The Molecular Chaperone HSP70 Binds to and Stabilizes NOD2, an Important Protein Involved in Crohn Disease*

Vishnu Mohanan† and Catherine Leimkuhler Grimes†‡§

From the Departments of † Biological Sciences and ‡ Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716

Background: NOD2, an innate immune receptor, senses bacterial cell wall fragments. NOD2 mutations are linked to Crohn disease.

Results: HSP70 enhances NOD2’s activity and increases its half-life.

Conclusion: NOD2 mutants are less stable than the wild type. HSP70 overexpression stabilizes the NOD2 Crohn mutants and rescues its activity.

Significance: Stabilization of the NOD2 mutants may provide an effective therapy for Crohn disease.

Microbes are detected by the pathogen-associated molecular patterns through specific host pattern recognition receptors. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an intracellular pattern recognition receptor that recognizes fragments of the bacterial cell wall. NOD2 is important to human biology; when it is mutated it loses the ability to respond properly to bacterial cell wall fragments. To determine the mechanisms of misactivation in the NOD2 Crohn mutants, we developed a cell-based system to screen for protein-protein interactors of NOD2. We identified heat shock protein 70 (HSP70) as a protein interactor of both wild type and Crohn mutant NOD2. HSP70 has previously been linked to inflammation, especially in the regulation of anti-inflammatory molecules. Induced HSP70 expression in cells increased the response of NOD2 to bacterial cell wall fragments. In addition, an HSP70 inhibitor, KNK437, was capable of decreasing NOD2-mediated NF-κB activation in response to bacterial cell wall stimulation. We found HSP70 to regulate the half-life of NOD2, as increasing the HSP70 level in cells increased the half-life of NOD2, and down-regulating HSP70 decreased the half-life of NOD2. The expression levels of the HSP70-associated NOD2 variants were less compared with wild type. The overexpression of HSP70 significantly increased NOD2 levels as well as the signaling capacity of the mutants. Thus, our study shows that restoring the stability of the NOD2 Crohn mutants is sufficient for rescuing the ability of these mutations to signal the presence of a bacterial cell wall ligand.

The human innate immune system is charged with a tremendous task, i.e. to provide the first line of defense against invading pathogens. This task is even more challenging in the human gut where over a trillion commensal bacteria reside. Thus, this ancient system must overlook the signal from the “good” bacteria while properly responding to the “bad” bacteria (1–3). To accomplish this daunting task, the system relies partially on a complex system of receptors known collectively as innate immune receptors or pattern recognition receptors (4). These receptors are made up of both Toll-like receptors (TLRs)2 and Nod-like receptors (5–8). It has recently been shown that these families of receptors work together to form an intricate set of feedback loops to ensure that the innate immune system properly responds to pathogenic and commensal bacteria (9, 10). One can imagine the consequences if there is a breakdown of one of the receptors. NOD2 (nucleotide-binding oligomerization domain-containing protein 2) has been shown to be mutated in Crohn disease, a gastrointestinal disorder affecting the upper intestines (11). Inohara and co-workers (12) have shown that the Crohn mutants of NOD2 do not properly respond to their corresponding bacterial signals. More than 58 mutations in the NOD2 gene have been linked with various diseases, and 80% of these mutations are reported to be linked with Crohn disease (13). The three highest point mutations with an association, R702W, G908R, and 1007fs, represent 32, 18, and 31%, respectively, of the total Crohn disease mutations (14) Normally, NOD2 participates in the innate immune response by sensing fragments of bacterial peptidoglycan (15). The human protein, NOD2, is found in peripheral blood mononuclear cells such as macrophages, granulocytes, dendritic cells, and along the intestinal epithelial cells (15–17). It has been shown that NOD2 binds to muramyl dipeptide (MDP), a small degradation fragment of the bacterial cell wall (18, 19). Upon binding to its bacterial cell wall fragment, NOD2 interacts with RIP2 to activate the canonical NF-κB pathway, triggering an inflammatory response (20). The Crohn-associated NOD2 mutants show a reduction in NF-κB signaling (12). NOD2 has a tri-domain structure consisting of two N-terminal caspase recruitment domains, a nucleotide binding domain, and a C-terminal leucine-rich repeat (21). Mutations in the LRR region of NOD2 have been shown to increase the incidence of Crohn disease (11, 22).

Given the importance of NOD2 to human inflammatory disorders, there has been an urgency to understand the proper

* This work was supported, in whole or in part, by National Institutes of Health Grant P20GM103541 from NIGMS.
† To whom correspondence should be addressed: Dept. of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716. Tel.: 302-831-2985; Fax: 302-831-6335; E-mail: cgrimes@udel.edu.
‡ The abbreviations used are: TLR, Toll-like receptor; HSP70, heat shock protein 70; HSP90, heat shock protein 90; GGA, geranylgeranylacetone; MDP, muramyl dipeptide; dox, doxycycline; co-IP, co-immunoprecipitation.
**HSP70 Regulates the Stability of NOD2**

signaling mechanism of NOD2 in the innate immune response. With the proper signaling cascade understood, treatments for Crohn disease can be developed. Recently, three independent studies have shed light on the control mechanisms of NOD2 signaling. First, Nunez and co-workers (23) demonstrated that NOD2 is negatively regulated by the protein Erbin. Erbin was shown to directly interact with NOD2, and its overexpression inhibited the ability of NOD2 to signal the presence of bacterial cell wall fragments (23). Elegant work by Kobayashi and co-workers (24) went on to show that NOD2 activation via MDP is regulated by proteosomal degradation. Before stimulation, NOD2 forms a complex with heat shock protein 90 (HSP90). Upon binding MDP, NOD2 and HSP90 dissociate. Subsequently, NOD2 undergoes proteosomal degradation (24). This unique mechanism allows NOD2 to tolerate a large influx of MDP and avoid septic shock. In a subsequent study, McDonald and co-workers (25) have shown that NOD2 is negatively regulated by the nucleotide synthesis enzyme carbamoyl-phosphate synthetase/aspartate transcarbamylase/dehydroorotase. Carbamoyl-phosphate synthetase/aspartate transcarbamylase/dehydroorotase was identified as a NOD2-interacting protein and was shown to inhibit the ability of NOD2 to signal the presence of bacterial cell wall ligands. Inhibition of carbamoyl-phosphate synthetase/aspartate transcarbamylase/dehydroorotase increased both the wild type and Crohn-associated NOD2 variants’ ability to signal the presence of bacterial cell wall ligands (25). Finally, independent genome-wide siRNA screens identified positive and negative regulators of the NOD2 or NF-κB pathways (26, 27).

In general, two different approaches have been used to identify protein-protein interactors involved in the NOD2-signaling cascade: 1) immunopurification (IP) followed by mass spectrometry and 2) siRNA screens (25, 27). Both approaches have been successful in identifying new protein-protein interactors of NOD2. However, the mechanism for rescuing the Crohn phenotype remains unresolved. To determine novel protein-protein interactors of NOD2, we designed a cell-based system that would allow for identification of interactors that used normal endogenous NOD2 levels in the cell and would allow for essential proteins to be identified. We were intrigued by the sophisticated system that would allow for identification of interactors that used normal endogenous NOD2 levels in the cell and would allow for essential proteins to be identified. We were intrigued by the sophisticated system that would give us a method to control the expression of an epitope-tagged version of NOD2 in human cells.

Using the tetracycline-regulated expression system, we have identified heat shock protein 70 (HSP70) as a bona fide interactor of NOD2. We show that HSP70 increases the half-life of both wild type and the Crohn mutant, NOD2. More importantly, we demonstrate that overexpression of HSP70 is able to rescue the Crohn mutant response to MDP, the bacterial cell wall fragment recognized by NOD2. Our data suggest that the Crohn mutants are inherently unstable and unable to properly respond to the bacterial cell wall ligands. Thus, a novel therapy providing stability to Crohn disease-associated NOD2 variants could be extremely useful.

**EXPERIMENTAL PROCEDURES**

**Cell Culture—**All cell lines used were obtained from American Type Culture Collection (ATCC, Manassas, VA). Phoenix-E cells were used for the generation of retroviruses. We used three cell lines as follows: 1) HEK293T, a human embryonic kidney cell line; 2) HCT 116, a human colon epithelial cell line; and 3) THP-1, a human monocyte cell line. All cell lines were cultured in DMEM, 10% FBS (Atlantic Biologicals), 2 mM t-glutamine, penicillin/streptomycin and grown in a humidified incubator at 37 °C and 5% CO₂.

**Construction of Tetracycline-regulated NOD2-expressing Stable Cell Lines—**Stable cell lines of HCT 116 and HEK293T cells that express tetracycline-inducible NOD2Myc under the control of RetroTET-ART system were created by viral infection with HRSp-NOD2Myc, transactivator (RTAh), and transresper (RTBg) as described previously (28, 31). Phoenix-E cells were used for the generation of retroviruses (32).

**Antibodies and Compounds—**Mouse monoclonal anti-Myc, rabbit monoclonal anti-Myc, rabbit monoclonal anti-HSP70, rat anti-HSP70, mouse monoclonal anti-β-actin, mouse monoclonal anti-laminin, and rabbit anti-RIP2 antibody were purchased from Cell Signaling Technology. Mouse monoclonal anti-HSP70 was purchased from Invitrogen. Alexa Fluor-594 goat anti-mouse and Alexa Fluor-488 goat anti-rabbit (Jackson ImmunoResearch) were used as secondary antibodies. Anti-mouse and anti-rabbit IgG HRP-linked secondary antibodies (Cell Signaling Technology) were used for immunoblot. Rabbit NOD2 antiserum, HM2559, was kindly provided by the Podolsky laboratory (33). MDP (Bachem) for stimulating the cells was used at a concentration of 2 μM. TNFα (Roche Diagnostics) for stimulating the cells was used at a concentration of 200 nM. HSP70 inhibitor KNK437 was obtained from Calbiochem. HSP70 inducer geranylgeranylace tone (GGA) was obtained from Sigma. Translational inhibitor cycloheximide was obtained from Sigma.

**Co-immunoprecipitation—**Cells were rinsed with 1× PBS, and the lysates were collected using freshly prepared lysis buffer (1% Triton X-100, 2 mM EDTA, 4 mM Na₃PO₄, 100 mM NaCl, 10 mM MES, pH 5.8, 10 mM NaF, 1 protease inhibitor mixture tablet (Roche Diagnostics)) and lysed by passing through a 21-gauge needle. 4 μg of lysates were mixed with the appropriate amount of antibody and incubated for 2 h in the cold. Lysate/antibody mixture was incubated with 40 μl of protein A Dynabeads (Invitrogen) (prewashed in PBS and lysis buffer) for 3 h in the cold. After 3 h, lysate/antibody bead mixture was washed four times using 200 μl of lysis buffer containing varying concentrations of NaCl as follows: wash 1, 100 mM NaCl; wash 2, 300 mM NaCl; wash 3, 500 mM NaCl; wash 4, 100 mM NaCl. To elute the proteins, two different methods were implemented depending on the downstream analysis as follows. 1) For Western blot analysis, proteins were eluted at 60 °C for 30 min with 2× reaction buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 12% glycerol, 0.008% bromphenol blue, 2% β-mercaptoethanol. 2) For mass spectrometry analysis, proteins were eluted with 5 μg/ml of Myc peptide (Sigma) in Tris-buffered saline.
(TBS) for 12 h at 4 °C. All eluates were analyzed by running in 7.5% polyacrylamide gels containing 0.1% SDS, followed by immunoblotting or staining using SYPRO® Ruby Protein Gel Stain according to the manufacturer’s instruction (Invitrogen). The immunoblot and mass spectrometry analysis procedures are described below.

**Mass Spectrometry Screen**—Samples were subjected to reduction/alkylation with dithiothreitil (Bio-Rad) and iodoacetamide (Sigma). Enzymatic digestion was performed with trypsin (Promega) at 37 °C. Subsequently, samples were desalted and concentrated using Ziptips (Millipore) and applied to target plates with α-cyano-4-hydroxycinnamic acid matrix (Sigma). Data were collected on a 4800 MALDI-TOF analyzer (ABSciex) in positive ion reflector mode over a mass range of 850–4000 Da, with internal calibration. Select peaks were further analyzed by MS-MS at 1 kV with default calibration. Combined MS and MS-MS data were submitted to Mascot (Matrix Science) and searched against NCBI with trypsin specificity, 100 ppm mass tolerance, 0.3 Da MS-MS tolerance, and the following variable modifications: carbamidomethylation and oxidation.

The search engine (Mascot) identifies potential hits within its database and calculates the probability of specific matches. We used a confidence interval, reported by ABSciex software based on the Mascot results, of 95% or greater, which can be thought of as similar to Mascot p < 0.05, for identity.

**Immunoblotting**—Cells were rinsed with 1× PBS, and an appropriate amount of lysis buffer (1% Triton X-100, 2 mM EDTA, 4 mM Na3PO4, 100 mM NaCl, 10 mM MES, pH 5.8, 10 mM NaF, 1 protease inhibitor tablet) was added and lysed using a 21-gauge needle. Protein quantification was performed using the Bradford assay using protein assay dye reagent concentrate according to the manufacturer’s instructions (Bio-Rad). Samples were prepared using 5× loading buffer (250 mM Tris-HCl, pH 6.8, 10% SDS, 30% glycerol, 0.02% bromphenol blue, 5% β-mercaptoethanol) and boiled for 5 min. The samples were electrophoresed in 7.5% polyacrylamide gels containing 0.1% SDS. Western transfer onto PVDF membrane was carried out using semi-dry transfer at 25 V for 1 h. 10% nonfat dry milk in TBS/Tween was used to block the membrane for 1 h and washed in TBS-T three times for 5 min each. The blots were incubated overnight at 4 °C with the appropriate amount of antibodies prepared in 1% milk. After three washes, the membrane was incubated with HRP-conjugated secondary antibody for 60 min at room temperature. Following secondary incubation, the blot was washed three times in TBS-T and incubated with the substrate (GE Healthcare) according to the manufacturer’s instructions. The blots were exposed to Fuji Super RX-U Half-Speed Blue films (Brandywine Imaging Inc.) in the dark room. All Western blots were performed at least three times independently. Using the replicates, the data were analyzed using ImageLab™. This analysis is reported alongside all Western blot images.

**Immunostaining**—HEK293T cells were transiently transfected with the pBKCMV/NOD2Myc plasmid using Lipofectamine 2000 (Invitrogen). After overnight incubation, the cells were plated on 24-well dishes containing glass coverslips. Once the cells were attached to the coverslips, they were washed two times with PBS. 4% paraformaldehyde solution in PBS was used for fixing the cells for 15 min at room temperature. The cells were then washed in PBS and treated with 0.3% Triton X-100 solution. Cells were treated with 5% normal goat serum for blocking and were incubated with rabbit monoclonal anti-Myc and mouse monoclonal anti-HSP70 antibodies. After overnight incubation, the cells were washed three times using PBS and incubated with Alexa Fluor-594 rabbit anti-goat and Alexa Fluor-488 mouse anti-goat sera. The cells were mounted on glass slides containing ProLong® gold antifade reagent with DAPI (Invitrogen).

**Half-life Determination**—Cycloheximide was used at a concentration of 100 µg/ml, and the lysates were collected every 4 h. GGA, KNK437, or DMSO was incubated 2 h prior to the addition of cycloheximide. For plasmid-induced protein expression studies, cycloheximide was added, and lysates were collected after 2 days of transfection.

**Plasmid Construction**—HRSp-NOD2Myc was constructed by amplifying NOD2 from pBKCMV vector and ligated into HRSp vector. BglIII and Ascl restriction sites were used to place the insert. The following primers were used to amplify NOD2: forward primer 5’-GAAGATCTGAGTGGAAGGGGAGGTTGGT-3’ and reverse primer 5’-TTGGCCGGCCTCACAGATCCTCTCCAGATGAGT-3’. The ligated products were transformed using HB101 competent cells. pBKCMV-NOD2/702MyC, pBKCMV-NOD2/908MyC, and pBKCMV-NOD2/1007insCMyc were constructed by amplifying the inserts from pFASTBac vector containing the various NOD2 mutants (previously constructed using site-directed mutagenesis) and ligated into pBKCMV vector. The following primers were used to amplify NOD2: forward primer 5’-CGCGGATCCCGCCGCTTAGGGAGAAACATGTTCTGAAAGAGATCTGATGGGGGAAGAGG-3’ and reverse primer 5’-CGGCCGCTCGAGTAAGAGCTGTAAGTGGTTTA-3’. The immunoblot and mass spectrometry analysis procedures are described below. The following primers were used to amplify NOD2: forward primer 5’-GAAGATCTGAGTGGAAGGGGAGGTTGGT-3’ and reverse primer 5’-TTGGCCGGCCTCACAGATCCTCTCCAGATGAGT-3’. The ligated products were transformed using DH5α competent cells. The above primers were used to construct K2605/NOD2Myc lentiviral vector. The lentiviral vector was used to make stable cell line as described previously (34).

**HSP70** was restriction-digested from pcDNA5/FRT/TO/HIS HSPA1A (Addgene, Plasmid 19537) using BamHI and XhoI restriction enzymes and ligated into pBKCMV vector. The following primers were used to amplify the ATPase domain and the substrate binding domain of HSP70: 1) ATPase domain forward primer 5’-GGCGGCCATCCTGAGTGTAAGAGCTGTAAGTGGTTTA-3’; 2) substrate binding domain reverse primer 5’-GCGGCCATCCTGAGTGTAAGAGCTGTAAGTGGTT-3’; 3) substrate binding domain forward primer 5’-GCGGCCATCCTGAGTGTAAGAGCTGTAAGTGGTTTA-3’; 3) substrate binding domain reverse primer 5’-TGGATGCTACCTCCTTAATGCTGAGGACCTGAC-3’. The above primers were used to construct K2605/NOD2Myc lentiviral vector. The lentiviral vector was used to make stable cell line as described previously (34).
Luciferase Reporter Assay—Lipofectamine 2000 was used to transiently transfect HEK293T cells, and Lipofectamine LTX was used to transfect HCT 116. pGL4.32 (luc2P/NF-κB-RE/Hygro) and pRL Renilla luciferase reporter vectors were used. An appropriate amount of plasmids were mixed with the transfection reagent and incubated overnight in cells seeded in 24-well dishes. Cells were incubated with 2 μM MDP or 200 nM TNFα for 6 h, and the lysates were collected to perform the Dual-Luciferase Reporter Assay (Promega) according to the manufacturer’s instructions and were normalized to Renilla activity. KNK437 or DMSO was treated 2 h prior to MDP stimulation.

ELISA—The media were collected and centrifuged at 200 × g, and the supernatant at 24-well dishes. Cells were incubated with 2 μM MDP or 200 nM TNFα for 6 h, and the lysates were collected to perform the Dual-Luciferase Reporter Assay (Promega) according to the manufacturer’s instructions and were normalized to Renilla activity. KNK437 or DMSO was treated 2 h prior to MDP stimulation.

RT-PCR—Total mRNA was isolated from the cells using a standard RNA extraction procedure (5′). mRNA was converted to cDNA via the manufacturer’s instructions using Bio-Rad reverse transcriptase kit. Quantitative PCR was performed to detect the level of NOD2 in various CD4+ T cells. The following primers were used to identify NOD2: forward primer 5′-CGG-GAGGCTCGGTTCCTCACAGGAGATAC-3′ and reverse primer 5′-ACCC-CGGGCTCATGATG-3′. The following primers were used to identify actin in the PCR: forward primer 5′-GCTCGTCGACGACAACGGCTC-3′ and reverse primer 5′-CAAACATGATCTGGGTCATCTTCTC-3′. Real time quantitative PCR were performed in ABI PRISM 7700 sequence detector (Applied Biosystems) according to the manufacturer’s instruction. Samples were run in a 25-μl mixture in the following PCR condition: initial denaturation at 95 °C for 10 min, followed by 40 cycles, which consisted of 95 °C for 20 s, 60 °C for 30 s, 72 °C for 1 min, and a final extension at 72 °C for 10 min. The products were electrophoresed on a 1% agarose gel and visualized by staining the gel using ethidium bromide. The relative amount of NOD2 mRNAs normalized to β-actin mRNA was calculated using the 2^−ΔΔCt method (35).

Data Analysis—Data presented are means ± S.D. of at least three repeats. Each experiment (NF-κB promoter activity and
Western blot. pBKCMV/NOD2Myc vector and stained for NOD2 using mouse anti-Myc antibody (1:2000) and rabbit anti-HSP70. DAPI was used to stain the nucleus.

Western blot was performed to detect NOD2 using Myc antibody (1:1000) and FLAG using FLAG antibody (1:500).

NOD2Myc/Tet-op (no dox), and HEK293T-NOD2Myc/Tet-op (no dox) cells stimulated with 2 μM MDP were analyzed by mass spectrometry as described under the "Experimental Procedures." NOD2 and HSP70 were identified.

C, co-IP performed using mouse anti-Myc antibody (1 μl/150 μl of lysate) in HEK293T-NOD2Myc/Tet-op (no dox), HCT 116-NOD2Myc/Tet-op (no dox), HEK293T, and HCT 116 cells and probed for HSP70 using rat anti-HSP70 antibody (1:1000) and rabbit anti-Myc antibody (1:1000). D, co-IP performed using rabbit anti-HSP70 antiserum HM2559 (2 μl/150 μl) or rabbit IgG in THP-1 cells and probed for HSP70 using rat anti-HSP70 antibody (1:1000) and NOD2 using rabbit NOD2 antiserum HM2559 (1:5000). E, co-IP performed using mouse anti-FLAG antibody (5 μl/150 μl of lysate) in HEK293T cells transfected with p8KCMV/ATPase (A-FLAG) or p8KCMV/substrate binding domain (S-FLAG). Western blot was performed to detect NOD2 using Myc antibody (1:1000) and FLAG using FLAG antibody (1:5000). F, HEK293T cells transiently transfected using p8KCMV/NOD2Myc vector and stained for NOD2 using mouse anti-Myc antibody (1:2000) and rabbit anti-HSP70. DAPI was used to stain the nucleus. WB, Western blot.

![Image](image_url)

**FIGURE 2. Interaction between NOD2 and HSP70.** A, co-IP (IP) were performed using 1 μl of mouse anti-Myc antibody per 150 μl of lysate (HEK293T-NOD2Myc/Tet-op, stimulated with 2 μM of MDP) and probed for RIP2 using rabbit anti-RIP2 antibody (1:1000). WB, Western blot. B, SYPRO®-stained 7.5% polyacrylamide gels showing the bands that were obtained through co-immunoprecipitation using mouse anti-Myc antibody in HEK293T, HEK293T-NOD2Myc/Tet-op (no dox), and HEK293T-NOD2Myc/Tet-op (no dox) cells stimulated with 2 μM of MDP. The visible bands were characterized using protein mass spectrometry as described under the “Experimental Procedures.” NOD2 and HSP70 were identified. C, co-IP performed using mouse anti-Myc antibody (1 μl/150 μl of lysate) in HEK293T-NOD2Myc/Tet-op (no dox), HCT 116-NOD2Myc/Tet-op (no dox), HEK293T, and HCT 116 cells and probed for HSP70 using rat anti-HSP70 antibody (1:1000) and rabbit anti-Myc antibody (1:1000). D, co-IP performed using rabbit anti-HSP70 antiserum HM2559 (2 μl/150 μl) or rabbit IgG in THP-1 cells and probed for HSP70 using rat anti-HSP70 antibody (1:1000) and NOD2 using rabbit NOD2 antiserum HM2559 (1:5000). E, co-IP performed using mouse anti-FLAG antibody (5 μl/150 μl of lysate) in HEK293T cells transfected with p8KCMV/ATPase (A-FLAG) or p8KCMV/substrate binding domain (S-FLAG). Western blot was performed to detect NOD2 using Myc antibody (1:1000) and FLAG using FLAG antibody (1:5000). F, HEK293T cells transiently transfected using p8KCMV/NOD2Myc vector and stained for NOD2 using mouse anti-Myc antibody (1:2000) and rabbit anti-HSP70. DAPI was used to stain the nucleus. WB, Western blot.

IL8 ELISA) was completed in at least four separate biological replicates (n = 4). These biological replicates included studies of cells plated on separate dishes. Western blots were performed on separate cell lysates at least three times.

Student’s t test was used to analyze difference between two groups. *, p < 0.05 was considered as significant.

**RESULTS**

**Tetracycline-regulated NOD2 Expression**—Previous studies have successfully used immunoprecipitation followed by mass spectrometry to identify novel protein-protein interactions. In our hands, this approach yielded a significant number of proteins. We reasoned that this was due to the unnaturally high concentrations of NOD2 present in the cell, and perhaps many of these interactions were artifacts of our initial experimental design. Thus, we opted for a system where the expression of epitope-tagged NOD2 mirrored that of endogenous levels. Although antibodies for NOD2 already exist, we used epitope-tagged NOD2 on either its N or C terminus. We did this for two reasons as follows: 1) the tag could be used across many constructs of NOD2 (wild type, Crohn-associated variants, truncations, and protein domains of NOD2), and 2) steric occlusion of pre-existing NOD2 antibodies could prevent NOD2 from binding to its interacting proteins.

Using the protocol described by Blau and co-workers (28), we successfully constructed tunable NOD2 (containing Myc tag) stable cell line in HEK293T (Fig. 1A). We showed that NOD2 levels (both protein and mRNA) increased with an increasing concentration of doxycycline (Fig. 1, A and B). It is not uncommon in the inducible cell lines to see leaking the promoter (i.e. expression of protein in the absence of doxycycline) (36). We observed low levels of NOD2 expression in the absence of doxycycline (Fig. 1, A and B). However, we thought that this very low expression of NOD2 might mirror the endogenously expressed cell line. We compared the expression of the regulated NOD2 (NOD2Myc/Tet-op (no doxycycline)) compared with the constitutively overexpressed NOD2 (NOD2Myc) in cell lines created by lentiviral vector K2605/NOD2 transduction. We found that NOD2 expression levels were over 257 times higher in the constitutively expressed system compared with the inducible system (Fig. 1, C and D). Moreover, we showed that the inducible expression system matched the expression of wild-type NOD2 in both THP-1, a monocyte cell line that endogenously expresses NOD2, and 2) HCT 116, an intestinal epithelium that has been shown to endogenously express NOD2 (Fig. 1D) (37).

With the desired inducible NOD2 system in hand, we set out to identify novel protein interactors of NOD2.

**Identification of HSP70 as a NOD2 Interactor**—Using the NOD2 inducible cell lines, we performed immunopurification followed by mass spectrometry. The experiment was performed in both the absence and presence of the NOD2 ligand MDP. No doxycycline was used in any of our experiments, as we showed that this amount of NOD2 best matches the endogenous levels (Fig. 1D). As a method to control for nonspecific interactions, several precautions were taken. First, we used...
HEK293T cells that did not express an epitope-tagged NOD2. Second, we performed extensive washing (four washes with increasing concentration of sodium chloride, see “Experimental Procedures” for more details) of the resin to ensure nonspecific proteins were removed. Finally, we selectively eluted NOD2 from the resin using low concentrations of Myc peptide. To validate our method, we first confirmed the presence of a known NOD2 interactor, RIP2 (Fig. 2A). Upon confirming our method, the interacting proteins were separated using SDS-PAGE, and proteins were detected using Sypro Ruby stain (Fig. 2B). Prominent bands were excised from the gel, trypsinized, and analyzed using electrospray ionization-mass spectrometry. In total, we identified six protein-protein interactors using mass spectrometry. Two of these proteins have already been identified as NOD2 interactors, actin and HSP90. Initially, we thought that the interaction of NOD2 and HSP70 might be an artifact of our experiment, as HSP70 is ubiquitously expressed in cells (38). However, HSP70 has recently been shown to control the innate immune system both by binding and inhibiting TLR4, as well as mediating decreases in lipotyic acid and TNFα-induced signaling (39–41). Thus, we were intrigued by the role that HSP70 could potentially play in regulating NOD2. We set out to validate our initial results.

First, we performed an IP experiment in the HEK293T-NOD2Myc/tet-op (no dox stimulation) cell line and HCT 116-NOD2Myc/tet-op (no dox stimulation). We confirmed that NOD2 interacted with HSP70 using Myc antibodies to immunopurify both cell lines (Fig. 2C). Next we assayed whether THP-1 cells, which endogenously express NOD2, interacted in HSP70. We found that HSP70 was immunopurified in these cells (Fig. 2D). To determine what portion of HSP70 interacts with NOD2, we expressed the two prominent domains of HSP70 as epitope tags, the ATP binding domain and substrate binding domain. Using co-immunopurification, we detected an interaction with only NOD2 in the substrate binding domain, leading us to believe that NOD2 interacts with HSP70 (Fig. 2E). In addition, immunostaining followed by confocal microscopy confirms that HSP70 and NOD2 interact in the cell (Fig. 2F). Thus, these data support that NOD2 interacts with HSP70 under physiological conditions. We were now curious to determine the function of this interaction in the context of innate immune signaling.

**HSP70 Regulates the Stability of NOD2**

HSP70 Regulates NOD2-induced NF-κB Activity—NOD2 is known to activate the NF-κB pathway upon stimulation from bacterial cell wall ligands (12, 15). A ligand for NOD2 is MDP.

---

**FIGURE 3. HSP70 regulates NOD2 induced NF-κB signaling.** A, dual-luciferase assay performed on HEK293T/NOD2Myc and HCT 116 transfected with HSP70 or control vector in the presence or absence of 2 μM MDP or 200 nM of TNFα incubated for 6 h. 75 ng of pGL432 and 7.5 ng of pRL vector was used per 24-well dish for transfection. Relative luciferase activity of firefly to Renilla is plotted. Results shown are the means ± S.D. of experiments performed in quadruplicate. *, p < 0.05 was considered as significant. B, dual-luciferase assay performed on HEK293T/NOD2Myc and HCT 116 cells incubated with 100 μM KNK437 or DMSO in the presence or absence of 2 μM MDP or 200 nM TNFα. 75 ng of pGL432, 7.5 ng of pRL vector, and 200 ng of HSP70 or control vector were used per 24-well dish for transfection. Relative luciferase activity of firefly to Renilla is plotted. Results shown are the means ± S.D. of experiments performed in triplicate. *, p < 0.05 was considered as significant. C, quantification using ELISA of the amount of IL-8 secreted by HCT 116, THP-1, and HEK293T/NOD2Myc cells incubated with 2 μM MDP or 200 nM TNFα in the presence of 100 μM KNK437 or DMSO. Results shown are the means ± S.D. of experiments performed in triplicate. *, p < 0.05 was considered as significant. D, quantification using ELISA of the amount of IL-8 secreted by HEK293T/NOD2Myc and HCT 116 cells transfected with HSP70 or control vector incubated with 2 μM MDP or 200 nM TNFα. Results shown are the means ± S.D. of experiments performed in triplicate. *, p < 0.05 was considered as significant.
We hypothesized that HSP70 plays a role in NOD2’s ability to signal through the NF-κB pathway. To test this hypothesis, we took a multipronged approach, overexpressing and decreasing the levels of HSP70 within the cell. We then analyzed the ability of NOD2 to induce NF-κB activation using the established luciferase NF-κB reporter assay. Briefly, this assay is a transfection assay in which the NF-κB promoter drives the expression of luciferase. When NF-κB is activated, higher levels of luciferase are expected. Previously, it has been shown that overexpression of HSP70 decreases the ability of TLR4 to signal via NF-κB.

Our results showed that NOD2 increased NF-κB activation when HSP70 was overexpressed in both NOD2-transfected (HEK293T) and a cell line containing endogenous NOD2 (HCT 116) (Fig. 3A). We saw no difference in NF-κB activation when HSP70 was overexpressed but not treated with MDP; thus, overexpression of HSP70 does not activate NF-κB (Fig. 3A). The difference in NF-κB activation was only present after the cells were stimulated with MDP. We also showed that the effect could be reversed by decreasing the expression of HSP70 (Fig. 3B). KNK437 is a small molecule that has been shown to specifically inhibit HSP70 at the mRNA level (42). When HCT 116 cells were treated with KNK437, we observed a decrease in the level of HSP70 mRNA (data not shown), and the same trend was observed in HEK293T-NOD2Myc/tet-op (no dox stimulation) (Fig. 4, C and D). Using the same luciferase assay described above, we observed that NOD2’s ability to signal the NF-κB pathway via MDP was significantly decreased when treated with HSP70 inhibitor (Fig. 3B). When the cells were treated with the inhibitor alone, there was no significant change in NF-κB activation. As a control, cells were also treated with TNFα, a known NF-κB activator (43). HSP70 overexpression and treatment with TNFα yielded a 9.7% increase in NF-κB activation, and treatment with KNK437 showed a 22.4% decrease in NF-κB activation. As a comparison, MDP showed a 59.9% increase upon HSP70 overexpression and 60.5% decrease upon KNK437 treatment. These data demonstrate that HSP70 regulates NOD2’s ability to signal to NF-κB.

To further support our data, we assayed NOD2’s ability to produce cytokines in both HSP70 overexpression or inhibition conditions. This assay avoided the use of the transfection of the reporter plasmid. Our data showed that IL-8, a pro-inflammatory cytokine that is known to be produced upon NOD2 activation, was significantly decreased when treated with HSP70 inhibitor (Fig. 3C). Again, TNFα was used as a control, and we saw the same trends as with the Dual-Luciferase assay. HSP70 overexpression and treatment with TNFα yielded a 19.7% increase in the amount of IL-8 secreted, and treatment with
KNK437 showed a 14.8% decrease in the amount of IL-8 secreted. As a comparison, MDP showed a 71.9% increase upon HSP70 overexpression and 42.3% decrease upon KNK437 treatment. These data confirm our hypothesis that HSP-70 positively regulates NOD2's ability to signal in the presence of bacterial cell wall ligands. We next aimed to determine the mechanism by which HSP70 regulates NOD2.

**HSP70 Regulates NOD2 Level in Cells**

HSP70 is a chaperone and has the ability to stabilize proteins (44, 45). We wondered whether HSP70 was affecting NOD2's stability in the cell. To test whether HSP70 alters NOD2 levels in the cell, we used three different conditions to control the expression of HSP70 as follows: 1) overexpression of HSP70 using transfection; 2) overexpression of HSP70 using the small molecule inducer GGA; and 3) inhibition of HSP70 with KNK437 (Fig. 4, A–C). We analyzed NOD2’s protein level using immunoblotting. Overexpression of HSP70 showed an increase in NOD2 levels (Fig. 4, A and B), and decreasing HSP70 showed a decrease in NOD2 levels (Fig. 4C). Moreover, we showed that the decrease in HSP70 using the small molecule inhibitor was dose-dependent (Fig. 4D). As the inhibitor concentration was increased, the concentration of HSP70 decreased as expected, and the amount of NOD2 also decreased. These data could explain the NOD2 signaling effects in changing concentrations of HSP70 (Fig. 3).

Thus, one can control NOD2 signaling by changing the concentration of HSP70 in the cell.

**HSP70 Regulates NOD2 Half-life**

As HSP70 is able to affect the level of NOD2 in the cell, it should change the half-life of NOD2 in the cell. We performed the classical protein half-life experiment using cycloheximide, a well documented translational inhibitor (46). Again, we used three approaches to control the levels of HSP70 as follows: small molecule activator, small molecule inhibitor, and overexpression using transfection. We showed that when HSP70 was overexpressed using GGA, there was a 2-fold increase in NOD2's half-life (Fig. 5A). Conversely, when HSP70 was inhibited using KNK437, there was a 2-fold decrease in NOD2's half-life (Fig. 5A). When the level of HSP70 was increased using transfection, again the level of NOD2 increased 2-fold (Fig. 5B). These data support that HSP70 is able to stabilize NOD2 and thereby directly affect its ability to signal.

**Decreased Stability of NOD2 Crohn Mutants**

It has previously been shown that the NOD2 Crohn-associated variants are defective in their ability to signal the presence of bacterial cell wall fragments via NF-κB (12, 22). We hypothesized that this difference is due to the inherent stability of the mutants as compared with the wild type. We used two approaches to quantify the stability of the NOD2 Crohn mutants. First, we transfected...
cells with equal amounts of either wild-type NOD2 or Crohn-associated NOD2 variants. The cells were harvested and subsequently analyzed for NOD2 using Western blot and mRNA using RT-PCR (Fig. 6, A and B). We found that the mutants were expressed significantly less than the wild type, even though they have the same amount of mRNA expressed in the cell. Interestingly, the frameshift NOD2 Crohn variant showed a severe decrease in protein levels. This variant is linked to a more detrimental phenotype in humans affected with Crohn disease. To support the idea that the Crohn mutants were unstable compared with the wild type, we performed the half-life experiments with the mutants. We found that the half-life of the mutants was significantly decreased compared with the wild type (Fig. 6C). This instability could provide an explanation of why the Crohn mutants cannot properly signal as efficiently as the wild type. We hypothesized that the Crohn mutants interact with HSP70, the protein that can affect the stability of wild-type NOD2.

**Increasing HSP70, Rescues NOD2 Mutant Activity**—To determine whether the Crohn mutants were capable of interacting with HSP70, we performed co-immunoprecipitation with HSP70 (Fig. 7A). Although we have previously shown that the mutant expression was less than the wild type (Fig. 6A), we expected that the immunopurification would be enriched for low levels of protein. We showed that all three mutants were able to purify endogenous HSP70. In addition, we probed whether overexpression of HSP70 would affect the level of the NOD2 mutants. When HSP70 is overexpressed using transfection, the levels of the Crohn mutants also increased in cells (Fig. 7B). Given that HSP70 increased both the stability and the ability for wild-type NOD2 to signal via NF-κB, we assayed whether HSP70 had the same effect on the Crohn mutants of NOD2. When HSP70 was overexpressed using transfection, we showed that the ability Crohn mutants’ to signal the presence of the bacterial cell wall ligand, MDP, was significantly increased (Fig. 7C). In two of the three Crohn-associated NOD2 variants, the level of NF-κB activation was restored to wild-type levels. These data imply that HSP70 is able to rescue the ability of the Crohn mutants to signal.

**DISCUSSION**

NOD2 is an important innate immune receptor that is responsible for sensing the occurrence of bacterial cell wall fragments within mammalian cells. It has been known for over 10 years that mutations in NOD2 correlate to the development of Crohn disease (11). Moreover, these mutations do not properly respond to bacterial cell wall components (12). Studies have shown that when cells containing the NOD2 mutations are treated with the bacterial cell wall fragments, a lower NF-κB response is obtained (12, 22). It has been suggested that a basal level of NOD2 activation is needed in the cell to control other innate immune receptors. Without the ability to activate NF-κB, an uncontrollable amount of inflammation ensues, and Crohn disease develops (47, 48). Much effort has been focused on trying to identify the mechanism by which NOD2 signals to the NF-κB response. Many protein interactors have been found. However, none explain the Crohn NOD2 phenotype, i.e. a lack of response to bacterial cell wall ligand.

To understand the mechanism of NOD2 signaling, we developed a novel system to screen for NOD2 protein-protein inter-
actors. Our approach has two main advantages over previous NOD2 studies. First, a tetracycline-inducible promoter system allowed a controllable, low level expression of NOD2 to be obtained (Fig. 1A). Second, the expression of an epitope-tagged NOD2 allowed for the efficient purification of NOD2 and the interacting proteins (Fig. 2B). The interacting proteins could then be identified using mass spectrometry. Our small screen identified HSP70 as a protein that interacts with NOD2. Initially, we were skeptical of the significance of this finding, as HSP70 is ubiquitously expressed in the cells, and we believed that this finding could be an artifact. However, recently HSP70 has been shown to regulate a number of innate immune receptors. Our study went on to validate HSP70 as a genuine NOD2 protein-protein interactor (Fig. 1, A and C). We showed that NOD2 interacts with the substrate binding domain of HSP70 (Fig. 2E). We investigated the role of HSP70 in NOD2 signaling using established cell-based assays to monitor NF-κB activation (Fig. 3, A and B). We observed that overexpression of HSP70 yielded an increase in NOD2's ability to signal when stimulated with MDP. The literature has reported that overexpression of HSP70 blocks the denaturation of IκB kinase thereby increasing the nuclear translocation of NF-κB (49). This could explain the increase in TNFα-induced activation (Fig. 3A), implying that more than just IκB kinase stabilization was necessary for the increase. We went on to show that HSP70 increases the half-life of NOD2 (Fig. 5, A and B). At this point, we wondered whether the half-life of the Crohn mutants was relative to the wild-type NOD2. We found that the Crohn mutants are inherently unstable, and their half-life is less than that of the wild-type protein (Fig. 6, A–C). This fact intrigued us, and we investigated whether the overexpression of HSP70 could provide a rescue mechanism for the NOD2 Crohn mutants, as the Crohn mutants also interact with HSP70 (Fig. 7A). We found that overexpression of HSP70 was able to restore the ability of the Crohn mutants to signal upon stimulation with MDP (Fig. 7C).

Overexpression of HSP70 to rescue a protein’s function is not a new phenomenon. There are many examples in the literature supporting this idea. For example, p53 and mutants of this protein are protected from degradation in the presence of excess HSP70 (50). In addition, human ether-a-go-go-related gene, a subunit of the potassium current I protein, is stabilized when HSP70 is overexpressed (51). Moreover, this study shows another protein (human ether-a-go-go-related gene) that HSP70 is capable of rescuing in its mutated form. An exciting outcome of our findings is that it suggests a potential method to treat Crohn disease, a small molecule that can specifically stabilize NOD2, by acting as a surrogate for the HSP70 protein.
Our study complements the finding by Kobayashi and co-workers (24) that NOD2 is rapidly degraded in the presence of MDP, as HSP90 is released. We found that NOD2 interacts with HSP70 independent of the presence of MDP, its bacterial cell wall ligand. Thus, HSP70 may provide a mechanism to reinitiate the ability of NOD2 to signal when there is a new burst of bacterial cell wall ligands. If, however, NOD2 is mutated, it is unable to signal the presence of bacterial cell wall fragments as its half-life in the cell is decreased. We found that overexpression of HSP70 is able to rescue NOD2’s response to bacterial cell wall ligands. We propose that HSP90 could play a similar role, and we are currently working to determine whether HSP90 interacts with the Crohn mutants. This mechanism is different from HSP70’s ability to alter the ability of TLR to signal. HSP70 (39) has been shown to specifically down-regulate the TLR4 response to lipopolysaccharide (39). Thus, the cell has designed HSP70 to be both an activator and an inhibitor of innate immune signaling.

In conclusion, we have developed a tetracycline-inducible NOD2 expression system that has allowed us to control the expression of NOD2 and purify interacting proteins. We have identified HSP70 as a novel NOD2 protein interactor. HSP70 is able to increase the half-life of NOD2 in the cell, and it also reinitiates the response of the Crohn-associated NOD2 mutants. We propose that small molecules that can specifically stabilize the NOD2 Crohn mutants may be useful in the treatment of Crohn disease.

Acknowledgments—We acknowledge Dr. John C. Kappes (University of Alabama, Birmingham) for kindly providing lentiviral vector K2605. We acknowledge Leila Choe and Professor Kelvin Lee at the University of Delaware Proteomics and Mass Spectrometry Facility, which is supported in part by the Delaware IDEA Network of Biomedical Research Excellence, National Institutes of Health Grant 8 P20 GM103446-13, for the mass spectrometry and protein identification. We thank Dr. Brian Bahnm and Amy Schaefer for critical reading of the manuscript.

REFERENCES
1. Janeway, C. A., Jr., and Medzhitov, R. (2002) Innate immune recognition. Annu. Rev. Immunol. 20, 197–216
2. Akira, S., Uematsu, S., and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell 124, 783–801
3. Medzhitov, R. (2007) Recognition of microorganisms and activation of the immune response. Nature 449, 819–826
4. Tosi, M. F. (2005) Innate immune responses to infection. Annu. Rev. Immunol. 23, 241–249
5. Wraith, S. D. (1999) Toll, a new piece in the puzzle of innate immunity. J. Exp. Med. 189, 605–609
6. Imler, J. L., and Hoffmann, J. A. (2001) Toll receptors in innate immunity. Trends Cell Biol. 11, 304–311
7. Brodsky, L., and Medzhitov, R. (2007) Two modes of ligand recognition by TLRs. Cell 130, 979–981
8. Martinon, F., and Tschopp, J. (2005) NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26, 447–454
9. Kinnebrew, M. A., and Pamer, E. G. (2012) Innate immune signaling in defense against intestinal microbes. Immunol. Rev. 245, 113–131
10. Abraham, C., and Medzhitov, R. (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729–1737
11. Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., Achkar, J. P., Brant, S. R., Bayless, T. M., Kirschner, B. S., Hanauer, S. B., Nuñez, G., and Cho, J. H. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411, 603–606
12. Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., Foster, S. J., Moran, A. P., Fernandez-Luna, J. L., and Nuñez, G. (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J. Biol. Chem. 278, 5509–5512
13. Borutzky, A., Fried, A., Chou, J., Bonilla, F. A., Kim, S., and Dedeoglu, F. (2010) NOD2-associated diseases: Bridging innate immunity and autoinflammation. Clin. Immunol. 134, 251–261
14. Lesage, S., Zouali, H., Cézard, J. P., Colombel, J. F., Belaiche, J., Almer, S., Tysk, C., O’Morain, C., Gassull, M., Binder, V., Finkel, Y., Modigliani, R., Gower-Rousseau, C., Macry, J., Merlin, F., Chamaillard, M., Jannot, A. S., Thomas, G., Hugot, J. P., EPWG-IBD Group, EPIMAD Group, and GETAID Group (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70, 845–857
15. Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., and Nuñez, G. (2001) NOD2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 276, 4812–4818
16. Gutierrez, O., Pipaon, C., Inohara, N., Fontalba, A., Ogura, Y., Prosper, F., Nuñez, G., and Fernandez-Luna, J. L. (2002) Induction of NOD2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J. Biol. Chem. 277, 41701–41705
17. Ogura, Y., Lala, S., Xin, W., Smith, E., Dowds, T. A., Chen, F. F., Zimmermann, E., Tretiakovka, M., Cho, J. H., Hart, J., Greenson, J. K., Keshav, S., and Nuñez, G. (2003) Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis. Gut 52, 1591–1597
18. Grimes, C. L., Ariyananda Lde, Z., Melnyk, J. E., and O’Shea, E. K. (2012) The innate immune protein NOD2 binds directly to MDP, a bacterial cell wall fragment. J. Am. Chem. Soc. 134, 13535–13537
19. Mo, J., Boyle, J. P., Howard, C. B., Monie, T. P., Davis, B. K., and Duncan, J. A. (2012) Pathogen sensing by nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP. J. Biol. Chem. 287, 23057–23067
20. Abbott, D. W., Wilkins, A., Asara, J. M., and Cantley, L. C. (2004) The Crohn’s disease protein, NOD2, requires RIP2 in order to induce ubiquitination of a novel site on NEMO. Curr. Biol. 14, 2217–2227
21. Strober, W., Murray, P. J., Kitani, A., and Watanabe, T. (2006) Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6, 9–20
22. Bonen, D. K., Ogura, Y., Nicolae, D. L., Inohara, N., Saab, L., Tanabe, T., Chen, F. F., Foster, S. J., Duerr, R. H., Brant, S. R., Cho, J. H., and Nuñez, G. (2003) Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124, 140–146
23. McDonald, C., Chen, F. F., Ollendorff, V., Ogura, Y., Marchett, S., Lécine, P., Borg, J. P., and Nuñez, G. (2005) A role for Erbin in the regulation of NOD2-dependent NF-κB signaling. J. Biol. Chem. 280, 40301–40309
24. Lee, K. H., Biswas, A., Liu, J. Y., and Kobayashi, K. S. (2012) Proteasomal degradation of NOD2 protein mediates tolerance to bacterial cell wall components. J. Biol. Chem. 287, 39800–39811
25. Richmond, A. L., Kabi, A., Homer, C. R., Marina-Garcia, N., Nickerson, K. P., Nevizhzhikai, A. L., Sreekumar, A., Chinnaiyan, A. M., Nuñez, G., and McDonald, C. (2012) The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology 142, 1483–1492
26. Lipinski, S., Grabe, N., Jacobs, G., Billmann-Born, S., Till, A., Häslar, R., Arden, K., Paulsen, M., Arlt, A., Kraemer, L., Hagemann, N., Erdmann, K. S., Schreiber, S., and Rosenstiel, P. (2012) RNAi screening identifies mediators of NOD2 signaling: implications for spatial specificity of MDP recognition. Proc. Natl. Acad. Sci. U.S.A. 109, 21426–21431
27. Warner, N., Burberry, A., Franchi, L., Kim, Y. G., McDonald, C., Sartor, M. A., and Nuñez, G. (2013) A genome-wide siRNA screen reveals positive and negative regulators of the NOD2 and NF-κB signaling pathways. Sci. Signal. 6, rs3
HSP70 Regulates the Stability of NOD2

28. Rossi, F. M., Guicherit, O. M., Spicher, A., Kringlestein, A. M., Fatyol, K., Blakely, B. T., and Blau, H. M. (1998) Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat. Genet. 20, 389–393

29. Onesto, C., Berra, E., Grépin, R., and Pagès, G. (2004) Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J. Biol. Chem. 279, 34217–34226

30. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., and Tschopp, J. (2005) Cardif is a adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167–1172

31. De Felipe, P., and Izquierdo, M. (2000) Tricistronic and tetracistronic retroviral vectors for gene transfer. Hum. Gene. Ther. 11, 1921–1931

32. Springer, M. L., and Blau, H. M. (1997) High-efficiency retroviral infection of primary myoblasts. Somat. Cell Mol. Genet. 23, 203–209

33. Hisamatsu, T., Suzuki, M., Reinecker, H. C., Nadeau, W. J., McCormick, B. A., and Podolsky, D. K. (2003) CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124, 993–1000

34. Mohanan, V., Temburni, M. K., Kappes, J. C., and Galileo, D. S. (2013) L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor. Clin. Exp. Metastasis 30, 507–520

35. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(− ΔΔC(T)) method. Methods 25, 402–408

36. Benabdellah, K., Cobo, M., Muñoz, P., Toscano, M. G., and Martin, F. (2011) Development of an all-in-one lentiviral vector system based on the original Tet for the easy generation of Tet-ON cell lines. PLoS One 6, e23734

37. Zhao, L., Kwon, M. J., Huang, S., Lee, J. Y., Fukase, K., Inohara, N., and Hwang, D. H. (2007) Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J. Biol. Chem. 282, 11618–11628

38. Mayer, M. P., Brehmer, D., Gassler, C. S., and Bukau, B. (2001) HSP70 chaperone machines. Adv. Protein Chem. 59, 1–44

39. Afrazi, A., Sodhi, C. P., Good, M., Jia, H., Siggers, R., Yazji, I., Ma, C., Neal, M. D., Prindle, T., Grant, Z. S., Branca, M. F., Ozojek, J., Chang, E. B., and Hackam, D. J. (2012) Intracellular heat shock protein-70 negatively regulates TLR4 signaling in the newborn intestinal epithelium. J. Immunol. 188, 4543–4557

40. Van Molle, W., Wielockx, B., Mahieu, T., Takada, M., Taniguchi, T., Sekikawa, K., and Libert, C. (2002) HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 16, 685–695

41. Vinokurov, M., Ostrov, V., Yurinskaya, M., Garbuz, D., Murashev, A., Antonova, O., and Evgen’ev, M. (2012) Recombinant human HSP70 protects against lipoteichoic acid-induced inflammation manifestations at the cellular and organismal levels. Cell Stress Chaperones 17, 89–101

42. Yokota, S., Kitahara, M., and Nagata, K. (2000) Benzyldiene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 60, 2942–2948

43. Schütze, S., Wiegmann, K., Machleidt, T., and Krönke, M. (1995) TNF-induced activation of NF-κB. Immunobiology 193, 193–203

44. Beckmann, R. P., Mizzen, L. E., and Welch, W. J. (1990) Interaction of HSP 70 with newly synthesized proteins: implications for protein folding and assembly. Science 248, 850–854

45. Young, J. C., Agashe, V. R., Siegers, K., and Hartl, F. U. (2004) Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 5, 781–791

46. Schneider-Poetsch, T., Ju, J., Eyler, D. E., Dang, Y., Bhat, S., Merrick, W. C., Green, R., Shen, B., and Liu, J. O. (2010) Inhibition of eukaryotic translational elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6, 209–217

47. Fava, F., and Danese, S. (2010) Crohn’s disease: bacterial clearance in Crohn’s disease pathogenesis. Nat. Rev. Gastroenterol. Hepatol. 7, 126–128

48. Noguchi, E., Homma, Y., Kang, X., Netea, M. G., and Ma, X. (2009) A Crohn’s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat. Immunol. 10, 471–479

49. Lee, K. H., Lee, C. T., Kim, Y. W., Han, S. K., Shim, Y. S., and Yoo, C. G. (2005) Heat shock protein 70 negatively regulates the heat-shock-induced suppression of the 1κB/1NF-κB cascade by facilitating 1κB kinase renaturation and blocking its further denaturation. Exp. Cell Res. 307, 276–284

50. Wiech, M., Olszewski, M. B., Tracz-Gaszewska, Z., Wawrzynow, B., Zylicz, M., and Zylka, A. (2012) Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 7, e51426

51. Li, P., Ninomiya, H., Kurata, Y., Kato, M., Miake, J., Yamamoto, Y., Igawa, O., Nakai, A., Higaki, K., Toyoda, F., Wu, J., Horie, M., Matsuura, H., Yoshida, A., Shirayoshi, Y., Hiroka, M., and Hisatome, I. (2011) Reciprocal control of hERG stability by HSP70 and Hsc70 with implication for restoration of LQT2 mutant stability. Circ. Res. 108, 458–468